Equity Overview
Price & Market Data
Price: $0.0314
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $8,925,889
Volume: 0
Performance Metrics
1 Week: -5.85%
1 Month: 24.11%
3 Months: 5.90%
6 Months: -17.96%
1 Year: -9.77%
YTD: -8.19%
Company Details
Employees: 18
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.